FAQ

Overall Survival

A measure of the time until death from any cause.

Topic mentions per year

Topic mentions per year

1962-2017
010002000300019622017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
PURPOSE Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Purpose Therapeutic prostate-specific antigen (PSA) –targeted poxviral vaccines for prostate cancer have been well tolerated… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
PURPOSE The prognostic value of genetic alterations characteristic of glioblastoma in patients treated according to present… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PURPOSE We previously reported that four cycles of docetaxel/cyclophosphamide (TC) produced superior disease-free survival (DFS… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
PURPOSE Objective tumor response rates observed in phase II trials for metastatic melanoma have historically not provided a… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
PURPOSE Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
PURPOSE Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
PURPOSE To investigate the prognostic value of tumor-infiltrating lymphocytes (TILs), especially regulatory T cells (Tregs), in… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The molecular portraits of breast tumors are conserved across microarray platforms
Validation of a novel gene expression signature in independent data sets is a critical step in the development of a clinically… (More)
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
The tumor microenvironment plays an important role in the biologic behavior of follicular lymphoma (FL), but the specific cell… (More)
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
Is this relevant?